This invention relates to the field of medicine and public polynucleotide 5 '3' new application kinase phosphatase, the expression of immunohistochemical staining in pancreatic carcinoma was significantly lower than that of adjacent tissues by immunohistochemical staining, and the expression of PNKP is lower, the higher the degree of malignancy of pancreatic cancer. It provides the application of polynucleotide kinase 5 '3' phosphatase in the preparation of products in the diagnosis of pancreatic cancer. The invention also provides Triptonide as polynucleotide kinase 5 'using 3' - phosphatase inhibitor. The invention further provides a polynucleotide kinase 5 '3' for the application of drug targets in the phosphatase preparation in the treatment of pancreatic cancer. Polynucleotide kinase 5 '3' phosphatase as a sign for the diagnosis of pancreatic cancer, the diagnosis of pancreatic cancer more accurately and quickly, as a drug target for the treatment of pancreatic cancer treatment target for treatment and a new way for the treatment of pancreatic cancer.
【技术实现步骤摘要】
多聚核苷酸-5’激酶-3’磷酸酶的新应用
本专利技术属于涉及药物领域,具体涉及多聚核苷酸-5’激酶-3’磷酸酶的新应用,进一步涉及多聚核苷酸-5’激酶-3’磷酸酶在制备诊断胰腺癌的产品中的应用和多聚核苷酸-5’激酶-3’磷酸酶在制备治疗胰腺癌的药物中的应用。
技术介绍
胰腺癌是胰腺细胞和导管细胞来源的恶性肿瘤。流行病学研究揭示,胰腺癌发病率呈持续升高趋势。胰腺癌是预后最差的恶性肿瘤,五年生存率仅6%。近三十年中,胰腺癌患者增加了6倍,且其发病率逐年升高。新发胰腺癌病例数逐年升高,流行病学专家预测,在未来三十年,胰腺癌很有可能成为癌症中第二致死数量的恶性肿瘤,对人类的危害将越来越大。近三十年来,尽管世界各国医务人员和研究者在抗胰腺癌治疗做了坚持不懈的努力,但胰腺癌患者五年生存率仅从3%提高至6%。虽然外科手术是治愈实体瘤的最有效治疗手段,但超过80%的胰腺癌患者在确诊时就已经在腹部扩散,或有多器官转移,错过了手术的最佳时机,外科手术已爱莫能助。在近20%可手术的胰腺癌患者中,即使接受最理想手术治疗(R0切除),术后患者的生存期也只有15-19月,5年生存率仅为20% ...
【技术保护点】
多聚核苷酸‑5’激酶‑3’磷酸酶作为胰腺癌标志物的应用。
【技术特征摘要】
1.多聚核苷酸-5’激酶-3’磷酸酶作为胰腺癌标志物的应用。2.多聚核苷酸-5’激酶-3’磷酸酶在制备诊断胰腺癌的产品中的应用。3.如权利要求2所述的应用,其特征在于,所述诊断胰腺癌的产品为RT-PCR诊断胰腺癌试剂盒、实时定量PCR诊断胰腺癌试剂盒、免疫检测诊断胰腺癌试剂盒或蛋白芯片诊断胰腺癌试剂盒。4.一种免疫检测诊断胰腺癌试剂盒,其特征在于,包括与多聚核苷酸-5’激酶-3’磷酸酶特异性结合的抗体。5.一种蛋白芯片诊断胰腺癌试剂盒,其特征在于,包括与多聚核苷酸-5’激酶-3’磷酸酶特异性结合的抗体。6....
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。